Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 3/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31153163 | 1.00 | MAPT (0.61) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL14723315 | 0.92 | MAPT (0.56) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL31150482 | 0.92 | MAPT (0.56) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL8370769 | 0.83 | MAPT (0.56) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL1266091 | 0.83 | MAPT (0.70) | MAPTKDM4EALDH1A1APEX1RECQL | |
| Benzene SCHEMBL28968025 | 0.79 | MAPT (0.52) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL14154810 | 0.78 | MAPT (0.63) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL30490133 | 0.78 | MAPT (0.63) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL14722647 | 0.76 | MAPT (0.56) | MAPTKDM4EALDH1A1APEX1RECQL | |
| SCHEMBL3050263 | 0.76 | MAPT (0.48) | MAPTKDM4EALDH1A1APEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642535-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS SIK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025119380-A1 | ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | 江苏威凯尔医药科技股份有限公司 | 2025-06-12 | — | — | WO | disclosed |
| CN-120118067-A | Estrogen receptor modulators and uses thereof | 江苏威凯尔医药科技股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2024141443-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS SIK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024141443-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS SIK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-04 | — | — | WO | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| EP-2049481-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | MAPT 2138/4885KDM4E 2561/4885ALDH1A1 2874/4885 |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | MAPT 1626/4885KDM4E 3474/4885ALDH1A1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.